PROTOCOL REVIEW AND MONITORING SYSTEM The UMCCC maintains two multidisciplinary committees for protocol review; the Protocol Review Committee (PRC) and the Cancer Prevention and Control PRC (CPC PRC). The objectives of the committees are: (1) To provide peer review of the scientific merit of all clinical trial research to be conducted at the University of Michigan Comprehensive Cancer Center (UMCCC) (2) To define priorities for the use of the Cancer Center resources (Clinical Trials Office, Cancer Center cores, space and patients) (3) To improve the overall quality of clinical research throughout the Cancer Center (4) To provide operational oversight to ensure sufficient scientific progress of supported protocols The PRC reviews all cancer-related therapeutic (including Phase I) clinical research protocols which use cancer center resources. This review is mandatory before submission to the institutional IRB. Additionally, correlative or imaging studies that involve informed consent and include Cancer Center patients are subject to committee review. Cancer control studies, prevention studies, health research and quality of life trials without a therapy component and other similar research protocols are reviewed by the CPC-PRC. Protocols that have been previously peer reviewed by recognized peer-review bodies are exempt from the scientific review by the full committee, but are administratively reviewed by the chair of the PRC or his/her designee. All new clinical research protocols and non-administrative amendments to active, previously approved trials are reviewed by the PRC. Studies not requiring review by the PRC and potentially eligible for review by the CPC-PRC include the following: (1) Studies without a treatment component (i.e. surveys, focus group trials, HRQOL trials). (2) Cancer prevention studies in non-cancer patients (3) Cancer control studies The UMCCC Protocol Review and Monitoring system adheres to all NIH, FDA and University of Michigan guidelines for the conduct of clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-21
Application #
7726824
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
21
Fiscal Year
2008
Total Cost
$86,515
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Harvey, Innocence; Stephenson, Erin J; Redd, JeAnna R et al. (2018) Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice. Endocrinology 159:2275-2287
Schuetze, Scott M; Bolejack, Vanessa; Thomas, Dafydd G et al. (2018) Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 4:814-820
Wagner, Vivian P; Martins, Manoela D; Martins, Marco A T et al. (2018) Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas. Sci Rep 8:2065
Hosoya, Tomonori; D'Oliveira Albanus, Ricardo; Hensley, John et al. (2018) Global dynamics of stage-specific transcription factor binding during thymocyte development. Sci Rep 8:5605
Schofield, Heather K; Tandon, Manuj; Park, Min-Jung et al. (2018) Pancreatic HIF2? Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. Cell Mol Gastroenterol Hepatol 5:169-185.e2
Su, Wenmei; Feng, Shumei; Chen, Xiuyuan et al. (2018) Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. Cancer Res 78:3207-3219
Moody, Rebecca Reed; Lo, Miao-Chia; Meagher, Jennifer L et al. (2018) Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. J Biol Chem 293:2125-2136
Ma, Vincent T; Boonstra, Philip S; Menghrajani, Kamal et al. (2018) Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clin Lymphoma Myeloma Leuk 18:e201-e210
Collins, Dalis; Fry, Christopher; Moore, Bethany B et al. (2018) Phagocytosis by Fibrocytes as a Mechanism to Decrease Bacterial Burden and Increase Survival in Sepsis. Shock :
Wang, Xuexiang; Dande, Ranadheer R; Yu, Hao et al. (2018) TRPC5 Does Not Cause or Aggravate Glomerular Disease. J Am Soc Nephrol 29:409-415

Showing the most recent 10 out of 1493 publications